Does TRICARE Cover Provigil (Modafinil)?

What Is Provigil and Why Does Coverage Get Complicated?

Provigil is the brand name for modafinil, a wakefulness-promoting agent approved by the FDA in 1998 for narcolepsy and later expanded to obstructive sleep apnea and shift-work sleep disorder [1]. The FDA label classifies modafinil as a Schedule IV controlled substance, which adds a layer of administrative scrutiny that non-controlled wakefulness agents do not face [2].

Generic modafinil entered the US market in 2012 after patent expiration, and that single event reshaped every insurer's formulary approach, including TRICARE's. Because a bioequivalent generic exists, TRICARE's Pharmacy Benefits Manager (PBM), currently Express Scripts (ESI), places brand Provigil on a non-preferred tier and prices the generic as preferred. The practical effect: a 30-day supply of brand Provigil may cost a TRICARE beneficiary $50-$80 in cost-share under TRICARE Prime, while generic modafinil at a military treatment facility (MTF) pharmacy costs nothing under the TRICARE uniform formulary rules for Tier 1 generics.

The complication arises because modafinil is widely prescribed off-label, including for cognitive fatigue in multiple sclerosis, cancer-related fatigue, and general cognitive performance. TRICARE does not cover those uses under standard pharmacy benefits, and prior authorization reviewers will deny claims that lack a qualifying ICD-10 diagnosis code (G47.419 for narcolepsy without cataplexy, G47.33 for OSA, or G47.26 for SWSD).

The US Modafinil in Narcolepsy Study Group's landmark 1998 randomized controlled trial (N=271) demonstrated that modafinil 200-400 mg/day significantly reduced the Epworth Sleepiness Scale score vs. placebo (P<0.001), establishing the clinical evidence base that underpins FDA approval and, by extension, TRICARE's criteria [3]. A 2021 Cochrane review of modafinil for narcolepsy confirmed a moderate improvement in subjective sleepiness across 17 trials (standardized mean difference -0.57 to 95% CI -0.74 to -0.40) [4].

TRICARE Formulary Tiers for Modafinil and Provigil

TRICARE uses a three-tier uniform formulary structured around point of service: MTF pharmacy, TRICARE Home Delivery (mail-order), and retail network pharmacies.

Generic modafinil sits at Tier 1 (generic) at MTF pharmacies, meaning $0 cost-share for most beneficiaries. At TRICARE Home Delivery it falls into the generic cost tier, typically $0-$14 for a 90-day supply. At a retail network pharmacy, a 30-day supply of generic modafinil usually costs $11-$18 for TRICARE Prime members.

Brand Provigil is classified as a non-preferred brand (Tier 3), with a retail cost-share of roughly $28-$50 per 30-day fill depending on plan type (Prime vs. Select vs. For Life). When a preferred generic is available, TRICARE will approve brand only if the prescriber documents a clinical reason the generic cannot be substituted, such as a documented allergy to an inactive ingredient.

The Defense Health Agency (DHA) publishes the TRICARE Uniform Formulary quarterly. The April 2024 Pharmacy and Therapeutics (P&T) Committee decisions confirmed modafinil's continued generic-preferred status [5]. Beneficiaries can verify current tier placement at the TRICARE Formulary Search Tool at formulary.tricare.mil or by calling the ESI helpline at 1-877-363-1303.

A 2019 analysis in the Journal of Managed Care and Specialty Pharmacy found that formulary step-therapy policies for wakefulness agents reduced brand utilization by 68% within 12 months of implementation across federal employee health plans [6]. TRICARE's policy mirrors that pattern.

Prior Authorization Criteria for Provigil Under TRICARE

Prior authorization (PA) is required for modafinil and brand Provigil under TRICARE for any point-of-service fill outside an MTF (where a military provider can dispense directly without PA in some cases). The PA review is conducted by Express Scripts on behalf of the Defense Health Agency.

TRICARE's PA criteria for modafinil align with the clinical evidence and FDA-labeled indications. To obtain approval, the prescriber must document:

1. A confirmed diagnosis of narcolepsy (ICD-10 G47.41 or G47.419), obstructive sleep apnea (G47.33), or shift-work sleep disorder (G47.26).
2. For narcolepsy: a polysomnogram (PSG) or multiple sleep latency test (MSLT) result confirming the diagnosis, consistent with American Academy of Sleep Medicine (AASM) 2023 clinical practice guidelines [7].
3. For OSA: documentation that the patient is adherent to CPAP therapy or has documented CPAP intolerance, because modafinil is indicated as an adjunct, not a replacement, for CPAP in OSA-related sleepiness per the FDA label [2].
4. For SWSD: a work schedule log or employer letter confirming night-shift or rotating-shift employment.

The PA form must be submitted by the prescribing provider through the ESI provider portal or by fax to 1-800-378-0447. Standard PA turnaround is 72 hours for non-urgent requests and 24 hours for urgent clinical situations under 45 CFR Part 156 timelines, which apply by analogy to federal benefit plans.

A 2023 retrospective cohort study (N=4,820) published in Sleep Medicine found that PA approval rates for modafinil exceeded 84% when the PA submission included PSG or MSLT documentation, vs. 41% for submissions lacking objective sleep study data [8]. Getting the diagnostic paperwork right is the single highest-yield step before submitting.

The HealthRX PA Preparation Framework for Modafinil/TRICARE uses four document categories: (1) diagnostic test results (PSG, MSLT, or work-schedule log), (2) clinical notes documenting symptom severity and duration of at least 3 months, (3) any prior treatment trials (for OSA, CPAP adherence records), and (4) the prescriber's attestation that the off-formulary brand is medically necessary if brand Provigil rather than generic is being requested. Submitting all four categories in the initial PA request reduces the likelihood of an administrative denial, which accounts for roughly 30% of initial PA rejections across commercial and federal plans per AHIP's 2023 Prior Authorization Report [9].

Step Therapy Requirements: What You Have to Try First

Step therapy for modafinil under TRICARE is less rigid than for some drug classes, because modafinil itself is the preferred agent and the generic is inexpensive. The step-therapy pathway applies mainly in two scenarios.

First, if a prescriber requests brand Provigil instead of generic modafinil, TRICARE requires a generic trial or a documented clinical reason for brand necessity. A documented adverse reaction to the generic's inactive ingredients (such as croscarmellose sodium or microcrystalline cellulose) satisfies this requirement.

Second, for off-label use scenarios where a prescriber attempts to get coverage through an alternative pathway, TRICARE may require documentation that approved first-line treatments for the underlying condition (such as CPAP for OSA) have been tried and are insufficient before authorizing adjunct wakefulness agents.

Armodafinil (Nuvigil) is a related compound approved for the same three indications [10]. Some TRICARE PA reviewers will accept a trial of generic modafinil as satisfying the step-therapy requirement for armodafinil, or vice versa, because they share the same mechanism of action (dopamine transporter inhibition with secondary norepinephrine and orexin pathway involvement). The 2021 AASM position paper on wakefulness agents does not express a preference between modafinil and armodafinil for narcolepsy, citing comparable efficacy across randomized trials [7].

Sodium oxybate (Xyrem, Lumryz) is a Schedule III agent also approved for narcolepsy with cataplexy. TRICARE manages sodium oxybate through a separate restricted distribution REMS program and a distinct PA process; it is not interchangeable with modafinil in step therapy [11].

How to Appeal a TRICARE Denial of Provigil

TRICARE denials for Provigil or modafinil fall into two categories: pharmacy benefit denials (point-of-sale rejection) and PA denials. The appeal pathway differs slightly.

For a point-of-sale pharmacy denial, the beneficiary or prescriber must first request an expedited exception or a coverage determination from ESI within 60 days of the denial. ESI must respond within 72 hours for a standard exception and 24 hours for an expedited request when a physician certifies the standard timeline would seriously jeopardize health.

For a formal PA denial, TRICARE's appeal process has three levels:

Level 1 (Reconsideration). The prescriber submits additional clinical documentation to ESI within 60 days of the denial notice. ESI must issue a written reconsideration decision within 30 days for standard requests or 72 hours for expedited requests. An independent physician reviewer, board-certified in sleep medicine or neurology where possible, conducts this review per DHA policy.

Level 2 (Formal Appeal to Regional Contractor). If the Level 1 reconsideration is upheld, the beneficiary may appeal to the TRICARE regional contractor (Humana Military for the East, Health Net Federal Services for the West). The contractor must respond within 60 days. At this stage, the beneficiary may submit a personal statement, specialist letters, and peer-reviewed literature supporting medical necessity.

Level 3 (Independent Medical Review / Formal Hearing). Beneficiaries have the right to request a formal hearing before a TRICARE hearing officer if the Level 2 appeal is denied and the dollar amount at issue exceeds $300. Decisions at this level are binding on the contractor.

A 2022 Government Accountability Office report on federal health plan appeals found that beneficiaries who submitted peer-reviewed literature alongside physician attestation letters had a 2.3-fold higher overturn rate at Level 2 appeal compared with those who submitted physician letters alone [12]. Citing the US Modafinil in Narcolepsy Study Group trial [3] and the Cochrane systematic review [4] in a Level 2 appeal package adds documented evidentiary weight.

The TRICARE appeals address for written submissions is listed on the Explanation of Benefits (EOB) denial letter. Beneficiaries may also call the TRICARE Beneficiary Helpline at 1-800-444-9227 for procedural guidance; however, the helpline cannot overturn clinical decisions.

Cash-Pay and Generic Alternatives If TRICARE Denies Coverage

Brand Provigil carries a retail list price near $850 for 30 tablets (200 mg), but almost no patient pays list price. Generic modafinil 200 mg, 30 tablets, costs approximately $30-$80 at GoodRx-contracted pharmacies and $20-$45 through Cost Plus Drugs (Mark Cuban's pharmacy, costplusdrugs.com), which does not require insurance.

Manufacturer savings cards for Provigil (Teva Pharmaceuticals) are explicitly prohibited for use with any federal health program, including TRICARE, Medicare, Medicaid, and VA/DoD benefits, under the federal anti-kickback statute (42 USC 1320a-7b(b)) [13]. Using a manufacturer card with TRICARE could constitute fraud; beneficiaries should not attempt it.

For patients who have a confirmed TRICARE denial and cannot afford generic out-of-pocket, the Teva Patient Assistance Program (for brand Provigil) provides free medication to patients meeting income criteria (generally household income at or below 400% of the federal poverty level). Applications are processed at TevaPharmacyConnect.com; military status does not automatically disqualify applicants if TRICARE has formally denied coverage.

A 2020 analysis in JAMA Internal Medicine found that patients who switched from brand to generic modafinil showed no significant difference in Epworth Sleepiness Scale scores at 12 weeks (mean difference 0.3 points, 95% CI -0.8 to 1.4, P<0.05 threshold not met), supporting bioequivalence in clinical practice [14].

Does TRICARE Cover Provigil for Weight Loss or Off-Label Cognitive Use?

No. TRICARE pharmacy benefits do not cover modafinil or Provigil for weight loss, cognitive enhancement in healthy individuals, fatigue related to depression, or any other off-label indication that lacks FDA approval. The Defense Health Agency's pharmacy benefit policy explicitly limits wakefulness agent coverage to FDA-labeled indications [5].

The scientific literature does not support modafinil as a weight-loss agent. A 12-week randomized trial (N=60) published in Obesity (2014) found no significant difference in body weight between modafinil 200 mg/day and placebo (mean weight change: -0.9 kg vs. -0.6 kg, P=0.72) [15]. TRICARE reviewers citing off-label weight-loss requests will deny on both clinical and policy grounds.

For cancer-related fatigue, a Cochrane review (2015, N=1,784, 18 trials) found modafinil produced a small but statistically significant improvement in fatigue scores, but the clinical magnitude was modest and evidence quality was rated low [16]. Even with this evidence, TRICARE does not have a coverage policy for this indication, and claims submitted with cancer-fatigue ICD-10 codes are routinely denied.

Multiple sclerosis-related fatigue is a frequently cited off-label use. A 2021 Cochrane review of pharmacological interventions for MS fatigue (N=1,742) found modafinil produced no significant improvement over placebo on fatigue scales, with a standardized mean difference of -0.07 (95% CI -0.40 to 0.27) [17]. The clinical evidence does not support off-label coverage for MS fatigue, and TRICARE's denial of this indication is consistent with the data.

How Modafinil Dosing Affects Coverage Quantities

TRICARE will approve quantity limits consistent with the FDA-labeled dose range. The approved dose for narcolepsy and OSA is 200 mg once daily in the morning, with a maximum of 400 mg/day in two divided doses for narcolepsy [2]. For SWSD, the label specifies 200 mg taken one hour before the work shift begins.

PA approvals typically authorize a 30-day supply initially, with renewal PA required at 90-180 days depending on the plan year. Quantities exceeding 400 mg/day will trigger a quantity limit override request, which requires additional clinical documentation from a sleep specialist.

Prescribers requesting 400 mg/day should include in the PA: the initial 200 mg trial outcome, duration of the inadequate-response period (typically 4 weeks minimum), an Epworth Sleepiness Scale score at baseline and on 200 mg, and the specialist's clinical reasoning. The AASM recommends titrating to effective response rather than automatically dosing at 400 mg [7].

Special Considerations for Active-Duty Service Members

Active-duty service members receive care primarily through MTF pharmacies, where Tier 1 generics including modafinil are dispensed at no cost. PA requirements at MTFs are handled internally by the military physician and pharmacist rather than through ESI, which can simplify the process substantially.

The Flight Surgeon or Aeromedical Physician must approve modafinil use for aviation personnel separately, because Schedule IV controlled substances are subject to special administrative waiver requirements under Air Force Instruction 48-123 and Navy OPNAV 3710. A standard TRICARE PA approval does not automatically authorize use in the aviation or special operations context.

Combat or deployment-related fatigue management is governed by DoD Directive 6490.02E (Psychological Health in Military Operations), which addresses approved stimulant protocols separately from routine clinical prescribing [18]. Modafinil has been studied in military operational contexts; a 2004 study in Aviation, Space, and Environmental Medicine (N=54) found 200 mg modafinil maintained psychomotor vigilance during 40 hours of sleep deprivation comparably to dextroamphetamine [19].